STAT3 signaling pathway in drug-resistant bladder cancer cell line

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway is implicated in tumor cell proliferation, apoptosis, and metastasis.
• The role of STAT3 in mediating drug resistance in cancer, particularly bladder cancer, remains largely undefined.

Purpose of the Study:

• To investigate the effects of STAT3 pathway inhibitors on drug-resistant bladder cancer cells.
• To analyze the impact of STAT3 inhibition on cell proliferation and metastasis in the context of drug-resistant bladder cancer.

Main Methods:

• Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) and Western blotting were used to assess gene and protein expression levels.
• Cell Counting Kit-8 (CCK-8) and wound healing assays were employed to evaluate cell proliferation and migration.
• The drug-resistant bladder cancer cell line Pumc-91/ADM was treated with the STAT3 inhibitor AG490.

Main Results:

• Drug-resistant Pumc-91/ADM cells exhibited decreased JAK2 and p-STAT3 expression and increased MMP2 expression compared to parental Pumc-91 cells.
• Inhibition of the STAT3 signaling pathway led to a significant reduction in mRNA and protein levels of STAT3, p-STAT3, MMP2, and Cyclin D1.
• AG490 treatment suppressed the proliferation and migration of Pumc-91/ADM cells.

Conclusions:

• The STAT3 signaling pathway plays a crucial role in regulating the proliferation and migration of drug-resistant bladder cancer cells.
• Modulation of Cyclin D1 and MMP2 expression by the STAT3 pathway is a key mechanism underlying drug resistance in bladder cancer.
• Targeting the STAT3 pathway presents a promising therapeutic strategy for overcoming drug resistance in bladder cancer.